ADC Therapeutics (ADCT) Total Liabilities (2019 - 2026)
ADC Therapeutics (ADCT) posted Total Liabilities of $507.9 million for Q1 2026, little changed sequentially from $509.0 million in Q4 2025, and down 0.57% YoY from $510.8 million in Q1 2025.
ADC Therapeutics (ADCT) Total Liabilities (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Total Liabilities for 8 years, with the latest figure at $507.9 million in Q1 2026.
- Quarterly Total Liabilities fell 0.57% year-over-year to $507.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $507.9 million (down 0.57% YoY) and the FY2025 annual result came in at $509.0 million, down 2.98% from the prior year.
- Total Liabilities steadied at $507.9 million in Q1 2026 per ADCT's latest filing, from $509.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $527.9 million in Q3 2025 and troughed at $405.1 million in Q2 2022.
- A 5-year average of $485.9 million and a median of $507.9 million in 2026 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 156.03% in 2022, down 8.96% in 2022.
- Over 5 years, Total Liabilities stood at $411.4 million in 2022, then climbed by 22.27% to $503.0 million in 2023, then rose by 4.29% to $524.6 million in 2024, then retreated by 2.98% to $509.0 million in 2025, then dropped by 0.22% to $507.9 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $507.9 million, $509.0 million, and $527.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | 507.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 507.58 Mn |
| Mar 31, 2026 | 507.87 Mn |
| Dec 31, 2025 | 508.98 Mn |
| Sep 30, 2025 | 527.94 Mn |
| Jun 30, 2025 | 520.75 Mn |
| Mar 31, 2025 | 510.76 Mn |
| Dec 31, 2024 | 524.62 Mn |
| Sep 30, 2024 | 521.03 Mn |
| Jun 30, 2024 | 503.45 Mn |
| Mar 31, 2024 | 502.42 Mn |
| Dec 31, 2023 | 503.03 Mn |
| Sep 30, 2023 | 521.08 Mn |
| Jun 30, 2023 | 515.89 Mn |
| Mar 31, 2023 | 429.99 Mn |
| Dec 31, 2022 | 411.41 Mn |
| Sep 30, 2022 | 426.98 Mn |
| Jun 30, 2022 | 405.12 Mn |
| Mar 31, 2022 | 419.22 Mn |
| Dec 31, 2021 | 451.88 Mn |
| Sep 30, 2021 | 450.67 Mn |